FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

Posts Tagged ‘pancreatic cancer’

January 6, 2020

New PARP Inhibitor Approval for Pancreatic Cancer

On December 27th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) – a type of targeted therapy known as a PARP inhibitor—for treatment of metastatic pancreatic cancer in people with a BRCA mutation.

May 7, 2019

Anti-vaccine Hype is a Threat to People with Cancer

Cancer treatment is challenging enough, without the added threat of a measles outbreak caused by decreased vaccinations.

January 31, 2019

Highlights from the 2018 Joining FORCEs Conference

Our Joining FORCEs conference informs, inspires and supports the hereditary cancer community. Judging from the feedback, last year’s October conference (our 11th!) once again successfully hit the mark. More than 700 people from the U.S. and other countries traveled to San Diego looking for more answers, deeper understanding, a stronger sense of community, clarity on … + read more

November 28, 2018

You Don’t Need a Family History of Cancer to Benefit from Genetic Testing

by Sue Friedman Many people mistakenly believe that genetic testing for inherited mutations in BRCA1, BRCA2, Lynch Syndrome, and other genes is only appropriate for people with many cases of cancer in their family. National guidelines—based on the latest research—state otherwise. There are situations where a single case of cancer in a family is enough … + read more

June 17, 2018

Solving for Y: Reaching Men About Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, Prostate And Related Cancers (HBOC)

by Sue Friedman Half of all people with an inherited BRCA, ATM, CHEK2, PALB2 or other mutation associated with HBOC are men. Nevertheless, the majority of awareness, research, and resources have focused on genetic testing in women. A recent article in JAMA highlights this disparity in BRCA testing between men and women. Emerging information on … + read more

May 30, 2018

Where’s FORCE? March and April

by Lisa Schlager “Where’s FORCE” highlights the ongoing efforts of FORCE staff and volunteers on behalf of the community. March As a member of the Bayer Oncology Patient Advocacy Advisory Council (PAAC), FORCE Vice President of Public Policy Lisa Schlager joined representatives from other advocacy groups and Bayer to review project proposals submitted by nonprofit … + read more

April 12, 2018

PARP Inhibitors and Hereditary Cancer: What’s New?

by Sue Friedman PARP inhibitors are drugs designed specifically to treat cancers in people with certain inherited mutations, including BRCA1 and BRCA2, among others. These drugs block an enzyme – known as PARP – used by cells to repair damage to their DNA. Although these agents seem to be most effective in people with mutations—not just … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered